Cargando…
Metabolic Shifts Induced by Fatty Acid Synthase Inhibitor Orlistat in Non-small Cell Lung Carcinoma Cells Provide Novel Pharmacodynamic Biomarkers for Positron Emission Tomography and Magnetic Resonance Spectroscopy
PURPOSE: Abnormal fatty acid (FA) synthesis is one of the common features of cancer. Fatty acid synthase (FASN), a multifunctional enzyme playing a key role in biosynthesis of FA, is up-regulated in prostate, breast, and lung carcinomas. Orlistat is a FDA-approved anti-obesity drug that inhibits the...
Autores principales: | Sankaranarayanapillai, Madhuri, Zhang, Nianxiang, Baggerly, Keith A., Gelovani, Juri G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591534/ https://www.ncbi.nlm.nih.gov/pubmed/22886728 http://dx.doi.org/10.1007/s11307-012-0587-6 |
Ejemplares similares
-
Mechanism of Orlistat Hydrolysis by the Thioesterase
of Human Fatty Acid Synthase
por: Fako, Valerie E., et al.
Publicado: (2014) -
The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
por: Seguin, F, et al.
Publicado: (2012) -
Head-to-head comparison of [(18)F]-fluorodeoxyglucose and [(18)F]-fluorocholine positron emission tomography/computed tomography in three patients with rare gestational trophoblastic neoplasms: A case series
por: Thientunyakit, Tanyaluck, et al.
Publicado: (2019) -
Pharmacodynamic testing and new validated HPLC method to assess the interchangeability between multi-source orlistat capsules
por: Zaid, Abdel Naser, et al.
Publicado: (2017) -
Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups
por: Gunay, Yasemin Emur, et al.
Publicado: (2023)